Pcn12 Use of Health Resources in Lung Cancer Patients: A Brazilian Analysis in the Private Payer Perspective

Stefani, Stephen; Brandalise, P

doi:10.1016/s1098-3015(10)70192-3

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No further publications were retained from the search of internet-based sources (such as disease-specific and patient advocacy websites and conference proceedings from ISPOR, ASCO, ECC, ESMO and the WCLC), as the 12 conference abstracts identified did not provide data specific to SCLC and costs [ 29 – 40 ].…”

Section: Resultsmentioning

confidence: 99%

The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature

Enstone

Greaney

Povsic

et al. 2017

PharmacoEconomics Open

View full text Add to dashboard Cite

BackgroundSmall cell lung cancer (SCLC), the most aggressive form of lung carcinoma, represents approximately 15% of all lung cancers; however, the economic and healthcare burden of SCLC is not well-defined.ObjectiveThe aim of this study was to explore the impact of SCLC on healthcare costs through a systematic literature review (SLR).MethodsUsing the OVID search engine, the SLR was conducted in PubMed, MEDLINE In–Process, EMBASE, EconLIT and the National Health Service Economic Evaluation Database (NHS EED). Searches were limited to studies published between January 2005 and 24 February 2016, and excluded preclinical studies. Additional internet-based searches were conducted. In total, 229 abstracts were retrieved and systematically screened for eligibility, with 17 publications retained.ResultsThe majority of publications provided data on limited and extensive disease of SCLC. The reported burden was categorised as direct costs and indirect costs, with the majority of the publications (n = 16) reporting on direct costs and one reporting on both direct and indirect costs. The only indirect costs reported for SCLC were lost productivity (premature mortality costs) and caregiver burden. Chemotherapy, diagnostic costs and treatment costs were identified as significant costs when managing SCLC patients, including the associated treatment costs such as hospitalisation, nurse visits, emergency room visits, follow-up appointments and outpatient care.ConclusionsSCLC and its treatment have a substantial impact on costs. The scarcity and heterogeneity of economic cost data negated meaningful cost comparison, highlighting the need for further research. Capturing the economic burden of SCLC may help patients and clinicians make informed treatment choices and improve SCLC management.

show abstract

Section: Resultsmentioning

confidence: 99%